Has Halle Berry confirmed she uses HRT?

Yes. Berry has publicly confirmed using hormone replacement therapy for menopausal symptoms in multiple interviews and on social media, beginning around 2021. She has not disclosed specific formulations or dosing.

What type of HRT does Halle Berry use?

Berry has not publicly disclosed her specific HRT regimen. Menopausal hormone therapy includes several options: transdermal estradiol patches, oral estradiol, topical gels, and various progesterone formulations. Without her disclosure, any claim about her specific protocol is speculation.

Can HRT explain Halle Berry's physique?

Only partially. HRT preserves the hormonal environment that supports muscle retention and bone density, but it is not anabolic. Berry's physique reflects years of consistent, high-intensity training in combination with hormonal optimization. HRT alone would not produce those results.

Is HRT safe for women over 50?

For women who start HRT within 10 years of menopause onset or before age 60, the benefit-risk balance is generally favorable according to the North American Menopause Society and reanalysis of the WHI data. Individual risk factors (history of breast cancer, clotting disorders, cardiovascular disease) must be assessed by a physician.

What did Halle Berry say to Congress about menopause?

In June 2024, Berry testified before the U.S. Senate in support of the Advancing Menopause Care and Mid-Life Women's Health Act. She described her own delayed perimenopause diagnosis and advocated for increased federal research funding and improved provider training in menopause medicine.

Halle Berry Transformation Timeline: Public Photos, Public Statements, and the Medical Context

By HealthRX.com Medical Team

Published May 25, 2026Updated May 25, 2026Last reviewed May 25, 2026

Clinical image for Halle Berry Transformation Timeline: Public Photos, Public Statements, and the Medical Context Image: HealthRX.com clinical image

Why Halle Berry's HRT Story Matters Clinically

Few public figures have been as direct about menopause as Halle Berry. Beginning around 2020, Berry started discussing her own experience with perimenopause, a misdiagnosis she says delayed proper treatment, and her decision to pursue hormone therapy. She later co-founded Respin, a platform that centers menopause wellness. In 2024, she testified before the U.S. Congress in support of expanded menopause research funding.

For the HealthRX.com Medical Team, Berry's story is clinically significant not because of who she is, but because the sequence she describes (delayed diagnosis, symptom misattribution, eventual HRT) mirrors patterns documented in large survey data. A 2019 Mayo Clinic survey found that only one in five OB-GYN residency programs provided any menopause medicine curriculum, contributing to the diagnostic delays Berry has described publicly.

At a glance

Status: Confirmed HRT use. Berry has stated on the record that she uses hormone therapy for menopausal symptoms.
Public disclosure began: Approximately 2020, with increasing detail through 2024.
Platform: Co-founded Respin, a wellness brand with menopause education as a core pillar.
Congressional testimony: Testified before the U.S. Senate in 2024 advocating for the Advancing Menopause Care and Mid-Life Women's Health Act.
Drug family: Menopausal hormone therapy (MHT), sometimes called HRT. Specific formulations have not been publicly disclosed.

Phase 1: The Misdiagnosis Period (Pre-2020)

Berry has described in multiple interviews, including a widely shared 2021 Instagram Live and a 2022 conversation with CNN, that she initially experienced symptoms she did not recognize as perimenopause. She has said her symptoms were attributed to other causes before a correct diagnosis was reached.

This is not unusual. Perimenopause can begin in a woman's early 40s and produce symptoms that overlap with thyroid dysfunction, mood disorders, and chronic fatigue. The 2022 Menopause Society position statement notes that vasomotor symptoms, sleep disruption, and cognitive changes frequently precede the final menstrual period by several years. Berry was in her early-to-mid 40s during this window, consistent with typical perimenopause onset between ages 40 and 44 for many women.

The HealthRX.com Medical Team take: Berry's story of misdiagnosis aligns with a systemic clinical gap. When a 42-year-old patient presents with brain fog, irregular sleep, and mood changes, perimenopause should sit high on the differential. The fact that it often does not reflects training deficits, not diagnostic complexity.

Phase 2: Public Disclosure and HRT Confirmation (2020-2022)

Starting around 2020, Berry began speaking openly about her menopause journey on social media and in press interviews. By 2021, she was explicitly discussing hormone therapy as part of her management plan. In a September 2021 interview with Women's Health magazine, Berry described hormone therapy as something that had changed her quality of life.

She has not publicly disclosed the specific hormone formulation she uses. This matters clinically because "HRT" is not one drug. The category includes:

Estradiol (oral, transdermal patch, topical gel): the bioidentical form of estrogen, considered first-line for vasomotor symptoms. A 2017 JAMA meta-analysis of 18 RCTs confirmed that estrogen therapy reduces hot flash frequency by roughly 75%.
Micronized progesterone (oral, e.g., Prometrium): used alongside estrogen in women with an intact uterus to prevent endometrial hyperplasia. The KEEPS trial showed that micronized progesterone paired with low-dose estradiol had a favorable cardiovascular and metabolic profile when started within six years of menopause.
Combined patches (estradiol + norethindrone or levonorgestrel): a single-application option delivering both hormones transdermally.
Low-dose vaginal estrogen: for genitourinary syndrome of menopause, sometimes used alongside systemic therapy.

The timing of initiation matters. The "timing hypothesis," supported by data from the WHI reanalysis and the Danish Osteoporosis Prevention Study, indicates that HRT started within 10 years of menopause onset (or before age 60) carries a different risk-benefit profile than HRT started later. Berry's public timeline suggests she began therapy in her mid-50s or possibly earlier, though exact dates are not confirmed.

Phase 3: Respin and the Advocacy Platform (2022-2024)

In 2022, Berry co-founded Respin (originally re-spin.com, now respin.com), a digital platform focused on health and wellness with a pronounced menopause vertical. The site features content about hormonal health, fitness, and nutrition.

Berry used the Respin platform to amplify her advocacy, but the clinical milestone came in 2024. She appeared before the U.S. Senate to support legislation expanding federal funding for menopause research and provider training. During her testimony, Berry described her own delayed diagnosis, called for Medicare coverage improvements for HRT, and argued that menopause care receives disproportionately low research funding relative to the number of women affected.

The HealthRX.com Medical Team take: Berry's pivot from personal disclosure to legislative advocacy is a meaningful public health development. The Advancing Menopause Care and Mid-Life Women's Health Act, which she testified in support of, targets the same training gap that the Mayo Clinic residency data identified. Whether the bill passes or not, the public attention has measurable value. Google Trends data for "menopause HRT" spiked during Berry's 2024 congressional appearance.

Phase 4: Fitness, Physical Changes, and What HRT Can (and Cannot) Explain

Berry's social media presence includes frequent fitness content. At age 57 (in 2024), she has posted training footage showing high-intensity exercise, martial arts work, and strength training. Media outlets have noted her physique, and some commentators have speculated about additional interventions beyond HRT.

It is important to be precise about what HRT does and does not do:

What HRT supports: Estrogen replacement preserves lean muscle mass indirectly by maintaining the hormonal environment that supports muscle protein synthesis. It also protects bone mineral density. A woman on adequate HRT has a physiological environment more favorable to retaining muscle and bone than a postmenopausal woman without replacement. HRT also improves sleep quality and reduces vasomotor symptoms, both of which support exercise recovery.

What HRT does not do: HRT is not anabolic in the way testosterone or growth hormone secretagogues are. Estrogen replacement does not build muscle beyond pre-menopausal baselines. The physique Berry displays is consistent with years of dedicated resistance training combined with hormonal optimization, not with HRT alone.

The HealthRX.com Medical Team take: Attributing Berry's fitness to HRT alone would be clinically inaccurate. HRT creates conditions (better sleep, preserved bone density, maintained estrogen signaling in muscle) that make training effective. The training itself does the work. This distinction matters for patients who expect HRT alone to reverse sarcopenia.

Side Effects and Risk Profile: What the Evidence Shows

No article about HRT is complete without the risk conversation. The Women's Health Initiative (WHI), published in 2002, initially reported increased breast cancer and cardiovascular risk with combined estrogen-progestin therapy. That finding shaped prescribing for two decades. Subsequent reanalysis and the 2024 Lancet Collaborative Group update clarified the picture:

Breast cancer: Combined estrogen-progestin therapy is associated with a small absolute increase in breast cancer risk (approximately 8 additional cases per 10,000 women per year of use). Estrogen-only therapy (for women without a uterus) showed no increase and possibly a decrease in some analyses.
Cardiovascular: When initiated in women under 60 or within 10 years of menopause, HRT is associated with reduced coronary events. The risk profile inverts for later initiation.
Venous thromboembolism: Oral estrogens increase VTE risk. Transdermal estradiol does not appear to carry the same risk, per the ESTHER study.
Common side effects: Breast tenderness, bloating, headache, and irregular bleeding (especially in the first 3-6 months).

Berry has not publicly discussed any side effects she has experienced.

What Berry Has Not Disclosed

Berry has confirmed HRT use but has not publicly stated:

The specific hormone formulation (estradiol patch, oral, gel, or compounded)
Whether she uses progesterone and in what form
Her dosing regimen or any dose adjustments over time
Whether she uses additional hormonal agents (DHEA, testosterone, etc.)

Some media sources have speculated about testosterone supplementation given her fitness level, but Berry has not confirmed this. The HealthRX.com Medical Team does not report speculation as fact. Low-dose testosterone for postmenopausal women is an area of active clinical research (the Global Consensus Position Statement endorses it only for hypoactive sexual desire disorder), but linking it to Berry without her confirmation would violate our editorial standards.

Frequently asked questions

›

References

Kling JM, et al. "Menopause Management Knowledge in Postgraduate Family Medicine, Internal Medicine, and Obstetrics and Gynecology Residents." Mayo Clin Proc. 2019. pubmed.ncbi.nlm.nih.gov/31568098
The 2022 Hormone Therapy Position Statement of The North American Menopause Society. Menopause. 2022. pubmed.ncbi.nlm.nih.gov/36156117
MacLennan AH, et al. "Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes." Cochrane/JAMA. 2017. jamanetwork.com
Harman SM, et al. "Kronos Early Estrogen Prevention Study (KEEPS)." Ann Intern Med. 2014. pubmed.ncbi.nlm.nih.gov/25051286
Rossouw JE, et al. "Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause" (WHI reanalysis). JAMA. 2007. pubmed.ncbi.nlm.nih.gov/17625141
Schierbeck LL, et al. "Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women" (DOPS). BMJ. 2012. pubmed.ncbi.nlm.nih.gov/23070644
Writing Group for the WHI. "Risks and benefits of estrogen plus progestin." JAMA. 2002. pubmed.ncbi.nlm.nih.gov/12117397
Canonico M, et al. "Hormone therapy and venous thromboembolism among postmenopausal women" (ESTHER study). Circulation. 2007. pubmed.ncbi.nlm.nih.gov/17062836
Davis SR, et al. "Global Consensus Position Statement on the Use of Testosterone Therapy for Women." J Clin Endocrinol Metab. 2019. pubmed.ncbi.nlm.nih.gov/31613873
Greising SM, et al. "Estradiol's effects on muscle." J Appl Physiol. 2019. pubmed.ncbi.nlm.nih.gov/31253696